<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01065857</url>
  </required_header>
  <id_info>
    <org_study_id>CF-PICOS2006</org_study_id>
    <nct_id>NCT01065857</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of CitraFleet (Sodium Picosulphate) as an Evacuating Treatment Prior to Colonoscopy.</brief_title>
  <official_title>Phase III, Multicenter, Randomized, Assessor-blind Study to Evaluate the Safety and Efficacy of CitraFleet (Sodium Picosulphate) as an Evacuating Treatment Prior to Colonoscopy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Casen-Fleet S.L.U.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Trial Form Support S.L.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Apices Soluciones S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratorios Casen-Fleet S.L.U.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine any significant differences in the efficacy and&#xD;
      acceptability between CitraFleet and Klean Prep® (polyethylene glycol) for the preparation of&#xD;
      gastrointestinal subjects undergoing a colon examination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The composite principal objective of the current study will therefore be, to determine any&#xD;
      significant differences in the joint variable of efficacy and acceptability between&#xD;
      CitraFleet and Klean Prep® (polyethylene glycol) for the preparation of subjects undergoing a&#xD;
      colon examination.&#xD;
&#xD;
      The evaluation will be carried out by two blinded assessors, independent of the investigator&#xD;
      who performed the procedure (endoscopist investigator). It will be assessed from images of&#xD;
      different sections of the colon: cecum, ascending, transverse, descending and rectum and&#xD;
      subsequent confirmation by Principal Investigator if an agreement has been reached between&#xD;
      the two blinded assessors or whether it is necessary to reach consensus.&#xD;
&#xD;
      The evaluation of the subject's acceptability will be assessed using a 5 point scale which&#xD;
      assesses the difficulty of taking the product, the degree of discomfort caused by it, and the&#xD;
      taste of the drug.&#xD;
&#xD;
      The secondary objective is to evaluate the safety of CitraFleet.&#xD;
&#xD;
      In addition a second exploratory arm of CitraFleet was included in this study (CitraFleet&#xD;
      Exploratory arm). The study is not powered to make formal statistical comparisons for this&#xD;
      arm. Exploratory assessment of this arm against the main CitraFleet regimen and Klean-Prep&#xD;
      will be made in order to run future trials design with this schedule.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects that achieve 'excellent' or 'good' cleansing in the Fleet® Grading Scale for Bowel Cleansing.</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects who find the agent easy to take or tolerable using a 5 point scale which assesses, the difficulty of taking the product, the degree of discomfort caused by it, and the taste of the drug, recorded in the subject questionnaire</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse reactions.</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">547</enrollment>
  <condition>Subjects Undergoing a Complete Exploratory Diagnostic Colonoscopy for the First Time.</condition>
  <arm_group>
    <arm_group_label>Citrafleet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The day prior to the colonoscopy in two dose times, first at 15:00h and second at 20:00h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Klean Prep</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The day prior to the colonoscopy from 16:00h to 20:00h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Citrafleet Exploratory</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The day of the colonoscopy in two dose times, first at 06:00h and second at 09:00h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium picosulphate, light magnesium oxide and anhydride citric acid.</intervention_name>
    <description>2 Single-dose sachets containing sodium picosulphate (0.01g/sachet), light magnesium oxide (3.50g/sachet) and anhydrous citric acid (10.97g/sachet).</description>
    <arm_group_label>Citrafleet</arm_group_label>
    <arm_group_label>Citrafleet Exploratory</arm_group_label>
    <other_name>Citrafleet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyethylene glycol, KCl, NaCl, sodium sulphate anhydrous and sodium bicarbonate.</intervention_name>
    <description>4 sachets containing Polyethylene glycol 3350 (59 gr), KCl (0.7425 gr), NaCl (1.465 gr), sodium sulphate anhydrous (5.685 gr), sodium bicarbonate (1.685 gr).</description>
    <arm_group_label>Klean Prep</arm_group_label>
    <other_name>KleanPrep PEG 4l</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who are between 18 and 80 years of age.&#xD;
&#xD;
          -  Subjects undergoing complete colonoscopy and therefore require prior preparation with&#xD;
             either Klean Prep® or CitraFleet.&#xD;
&#xD;
          -  Subjects capable of maintaining appropriate oral hydration during the intestinal&#xD;
             preparation process.&#xD;
&#xD;
          -  Subjects that have provided written informed consent.&#xD;
&#xD;
          -  Subjects in whom the use of any of the study drugs (KleanPrep®,CitraFleet) is not&#xD;
             contraindicated.&#xD;
&#xD;
          -  Subjects who can communicate with the study personnel and comply with study&#xD;
             requirements.&#xD;
&#xD;
          -  Subjects undergoing a complete exploratory diagnostic colonoscopy for the first time.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe renal insufficiency.&#xD;
&#xD;
          -  Ascites.&#xD;
&#xD;
          -  Congestive heart failure.&#xD;
&#xD;
          -  Gastrointestinal obstruction, gastric retention, intestinal perforation and/or ileus.&#xD;
&#xD;
          -  Megacolon and/or toxic colitis.&#xD;
&#xD;
          -  Nausea and/or vomiting and/or abdominal pain.&#xD;
&#xD;
          -  Severe dehydration.&#xD;
&#xD;
          -  Hypermagnesemia.&#xD;
&#xD;
          -  Rhabdomyolysis.&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  Subjects who have participated in a clinical trial in the previous 30 days.&#xD;
&#xD;
          -  Abdominal surgery for any acute process (for example acute appendicitis).&#xD;
&#xD;
          -  Active inflammatory intestinal disease.&#xD;
&#xD;
          -  Known allergy to any of the active ingredients or excipients of the study drugs.&#xD;
&#xD;
          -  Subjects not providing written informed consent.&#xD;
&#xD;
          -  Subjects not complying with all of the inclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel A. Muñoz-Navas, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clínica Universitaria de Navarra</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Infanta Elena</name>
      <address>
        <city>Valdemoro</city>
        <state>Madrid</state>
        <zip>28340</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Basurto</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Universitari Vall´d Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Clínic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. General Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Universitario Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Regional Universitario Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Universitario La Fé</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>February 8, 2010</study_first_submitted>
  <study_first_submitted_qc>February 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2010</study_first_posted>
  <last_update_submitted>April 14, 2011</last_update_submitted>
  <last_update_submitted_qc>April 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Ángel Navarro Lima, M.D. / European Medical Affairs Director</name_title>
    <organization>Laboratorios Casen-Fleet S.L.U.</organization>
  </responsible_party>
  <keyword>Colonoscopy, Preparation, Evacuating, Bowel Cleansing.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Picosulfate sodium</mesh_term>
    <mesh_term>Sodium sulfate</mesh_term>
    <mesh_term>Magnesium Oxide</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sodium Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

